EQS-News: MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
EQS-News: Formycon AG
/ Key word(s): Agreement
Presse Release // December 09, 2024 MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the commercialization of FYB202, Formycon’s Biosimilar to Stelara®1 (ustekinumab), in the Middle East and North Africa (“MENA region”). MS Pharma is a leading regional pharmaceutical company in the MENA region and specializes in the distribution of biotechnological as well as generic drugs. The company will have rights to license, commercialize and produce FYB202 locally at its new Biosimilars site in Saudi Arabia for the Gulf Cooperation Council (GCC) countries as well as further countries of the MENA region. In February 2023, Formycon entered into a license agreement with Fresenius Kabi for the commercialization of FYB202 in key global markets. As part of this agreement, Formycon retained the rights to separately out-license FYB202 for commercialization in specific countries of the MENA region. “Since the launch of our Lucentis®2 biosimilar FYB201 in the MENA region, we have established a very successful partnership with MS Pharma which was recently strengthened by adding the second ophthalmic biosimilar FYB203 (aflibercept) to this collaboration. It is our great pleasure to announce that we have now signed a further license and supply agreement with MS Pharma and added our FYB202 / ustekinumab biosimilar to this alliance. We are convinced that MS Pharma’s strong presence in the MENA region will support a good up-take of FYB202 as an effective, safe and cost-efficient treatment option for the numerous patients suffering from severe, chronic inflammatory diseases in the Middle East and North Africa. Formycon will receive an upfront payment as well as royalty payments from sales according to the agreement”, said Nicola Mikulcik, CBO of Formycon AG. "Expanding our biosimilar pipeline with ustekinumab enables us to address additional therapeutic areas within our specialty business, enhancing patient access to these vital treatments across the MENA region. Our successful collaboration with Formycon continues to grow stronger, and the addition of new products fortifies our pipeline further. Crucially, all our biosimilar products will be manufactured locally at our state-of-the-art facility in Saudi Arabia, ensuring a reliable local supply and aligning with the Kingdom’s ambitious biotech strategy." said Kalle Känd, CEO of MS Pharma. In September 2024, both the U.S. Food and Drug Administration (FDA) and the European Commission granted approval for the ustekinumab biosimilar FYB202. MS Pharma plans to submit for regulatory approval in MENA countries at the earliest opportunity. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 and is used in the treatment of severe inflammatory diseases in the fields of gastroenterology, dermatology, and rheumatology.
About Formycon: Formycon AG is headquartered in Munich and is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/ About MS Pharma: About Biosimilars: Contact: Tel.: +49 (0) 89 - 86 46 67 149 Disclaimer:
09.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Formycon AG |
Fraunhoferstraße 15 | |
82152 Planegg-Martinsried | |
Germany | |
Phone: | 089 864667 100 |
Fax: | 089 864667 110 |
Internet: | www.formycon.com |
ISIN: | DE000A1EWVY8 |
WKN: | A1EWVY |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2046341 |
End of News | EQS News Service |
|
2046341 09.12.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
The most important financial data at a glance | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Sales1 | 42,99 | 33,16 | 34,23 | 36,97 | 42,50 | 77,70 | 62,00 | |
EBITDA1,2 | 8,03 | -1,36 | -4,81 | -12,39 | -15,87 | 1,52 | -22,00 | |
EBITDA-Margin3 | 18,68 | -4,10 | -14,05 | -33,51 | -37,34 | 1,96 | -35,48 | |
EBIT1,4 | 7,13 | -2,27 | -5,73 | -13,33 | -17,73 | -0,37 | -23,40 | |
EBIT-Margin5 | 16,59 | -6,85 | -16,74 | -36,06 | -41,72 | -0,48 | -37,74 | |
Net Profit (Loss)1 | 7,10 | -2,29 | -5,93 | -13,48 | 35,99 | 75,80 | -27,00 | |
Net-Margin6 | 16,52 | -6,91 | -17,32 | -36,46 | 84,68 | 97,56 | -43,55 | |
Cashflow1,7 | 13,30 | -1,48 | -5,10 | -14,18 | -18,88 | -9,85 | 0,00 | |
Earnings per share8 | 0,71 | -0,23 | -0,54 | -1,22 | 2,59 | 4,72 | -1,35 | |
Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
INVESTOR-INFORMATION | ||||||
©boersengefluester.de | ||||||
Formycon | ||||||
WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
A1EWVY | DE000A1EWVY8 | AG | 906,19 Mio € | 20.12.2010 | Halten | 8FWH4F62+Q8 |
PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
64,13 | 27,32 | 2,35 | 129,22 | 1,80 | -92,02 | 11,66 |
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
0,00 | 0,00 | 0,00 | 0,00% |
Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
12.06.2024 | 08.05.2024 | 13.08.2024 | 28.11.2024 | 25.04.2024 |
Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
+2,05% | +5,10% | -9,04% | -4,65% | +414,39% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.